These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1273544)

  • 41. [Treatment of pulmonary tuberculosis of native Black Africans a chemotherapeutic regime including rifampicin (apropos of 75 patients)].
    Ayad M; Hane A; Kane PA
    Dakar Med; 1980; 25(1):65-74. PubMed ID: 7460740
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. The second study: a study on the combined therapy of rifampicin with ethambutol and pyrazinamide, especially on intermittent therapy].
    Kekkaku; 1972 Dec; 47(12):457-66. PubMed ID: 4652424
    [No Abstract]   [Full Text] [Related]  

  • 43. [Results of the treatment of newly detected pulmonary and pleural tuberculosis at the Lung Disease and Tuberculosis Clinic of the Białystok Medical Academy 1980-1984].
    Lukjan Z; Pregowski W; Zagórecka A; Kowal E
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():209-18. PubMed ID: 3154975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacokinetics of rifampicin].
    Kohno H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1987 Jan; 25(1):32-7. PubMed ID: 3599578
    [No Abstract]   [Full Text] [Related]  

  • 45. Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi.
    Beadsworth MB; van Oosterhout JJ; Diver MJ; Faragher EB; Shenkin A; Mwandumba HC; Khoo S; O'Dempsey T; Squire SB; Zijlstra EE
    Int J Tuberc Lung Dis; 2008 Mar; 12(3):314-8. PubMed ID: 18284838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Bacteriological relapse among the previously treated advanced pulmonary tuberculosis patients whose sputum converted to negative by the rifampicin treatment, with special reference to the duration of rifampicin administration (author's transl)].
    Yamamoto M; Morishita M; Hirano Y; Nagata A; Yazaki M
    Kekkaku; 1974 Jul; 49(7):195-9. PubMed ID: 4214961
    [No Abstract]   [Full Text] [Related]  

  • 47. [Intermittent administration of rifadine in destructive forms of pulmonary tuberculosis].
    Sobolevskaia LI; Korobko GV
    Vrach Delo; 1975 Apr; (4):60-2. PubMed ID: 1216820
    [No Abstract]   [Full Text] [Related]  

  • 48. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis.
    Zutshi RK; Singh R; Zutshi U; Johri RK; Atal CK
    J Assoc Physicians India; 1985 Mar; 33(3):223-4. PubMed ID: 4044481
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Results of treatment of chronically infectious patients with rifampicin in various combinations and in various models].
    Górecki R; Stanek S
    Gruzlica; 1974 May; 42(5):411-6. PubMed ID: 4464229
    [No Abstract]   [Full Text] [Related]  

  • 51. Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009.
    Arya A; Roy V; Lomash A; Kapoor S; Khanna A; Rangari G
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):440-5. PubMed ID: 25860000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Serum rifampicin level in children with tuberculosis and in young mice].
    Zwolska-Kwiek Z; Ceglecka-Tomaszewska K; Ziółkowski J
    Pneumonol Pol; 1982 Nov; 50(11):571-9. PubMed ID: 6985082
    [No Abstract]   [Full Text] [Related]  

  • 53. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
    LoBue PA; Moser KS
    Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
    Dubra F
    Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
    [No Abstract]   [Full Text] [Related]  

  • 56. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Sequential development of vitamin D metabolites under isoniazid and rifampicin therapy].
    Toppet M; Vainsel M; Vertongen F; Fuss M; Cantraine F
    Arch Fr Pediatr; 1988 Feb; 45(2):145-8. PubMed ID: 2898926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioavailability of rifampicin capsules.
    Buniva G; Pagani V; Carozzi A
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):404-9. PubMed ID: 6688798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of age and sex on bone mineral density in dialysis patients.
    Grzegorzewska AE; Młot-Michalska M
    Adv Perit Dial; 2007; 23():77-81. PubMed ID: 17886608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.